Skip to main content

Product News

 

Clinical courses

 

Clinical courses

  • Cefaly gets FDA approval for marketing - First medical device approved to prevent migraine

    U.S. Food and Drug Administration allowed marketing of the first device, Cefaly-manufactured by STX-Med in Belgium, as a preventative treatment for migraine headaches. This is also the first transcutaneous electrical nerve stimulation (TENS) device specifically authorized for use prior to the onset of pain.

  • Atorvastatin Beats Rosuvastatin in Protecting Kidneys in Diabetic and Nondiabetic Patients

    July 2, 2010 (Munich, Germany) — Results of 2 related trials investigating the effects of statins on urinary protein excretion and kidney function found atorvastatin (ATV) protective and rosuvastatin (RSV) unprotective, and possibly harmful, in diabetic and nondiabetic patients.

Subscribe to Product News